A REVIEW OF THE MOST OFTEN USED MEDICINES IN THE TREATMENT OF FUNGAL INFECTIONS
DOI:
https://doi.org/10.56782/pps.56Keywords:
antifungal drugs, fungal infectionsAbstract
Effective treatment of fungal infections depends on a proper selection of the antifungal agents. A number of medicines have been recently introduced into antifungal therapy differing by the chemical structure and mechanism of action. Antifungal resistance, toxicity, drug interactions and expenses limit current treatment strategies. The search for novel, more effective and less toxic antifungal drugs is in progress.
Downloads
References
Chmielewska L., Krasowska A.: Antybiotyki nie zawsze nasi sprzymierzeńcy. "Aura. Ochrona środowiska"- miesięcznik popularnonaukowy Naczelnej Organizacji Technicznej, Wydawnictwo Czasopism i Książek Technicznych SIGMA-NOT Sp. z o.o. 2001, sierpień, Warszawa.
Janiec W., Krupińska J.: Farmakodynamika. Podręcznik dla studentów farmacji. Wydawnictwo Lekarskie PZWL, Wydanie V unowocześnione. 2002;1004-1008.
Nowicki R.: Farmakoterapia grzybic powierzchniowych: http://www.vita.csc.pl/farmakoterapia.php.
Kaczmarek J., Bocheńska-Marciniak M.: Grzyby i ich udział w chorobach alergicznych. Terapia Alergologia. 2002;119:47-53.
Braham C., Ezzine Sebai N., Arrese J.E., et al.: Il y a sports et spores. Le pied, ses mycoses et onychomycoses. Rev. Med. Liege. 2001;56(11):773-776.
Lacroix C., Baspeyras M., de La Salmoniere P., et al.: Tinea pedis in European marathon runners. JEADV. 2002;16:139-142. DOI: https://doi.org/10.1046/j.1468-3083.2002.00400.x
Hay R.J., Robles W., Midgley G., et al.: Tinea capitis in Europe: new perspective on an old problem. JEADV. 2001;15:229-233. DOI: https://doi.org/10.1046/j.1468-3083.2001.00214.x
Rinaldi M.G.: Dermatophytosis: epidemiological and microbiological update. J. Am. Acad. Dermatol. 2000;43(5):120-124. DOI: https://doi.org/10.1067/mjd.2000.110378
Scheynius A., Johansson C., Buentke E., et al.: Atopic Eczema/Dermatitis Syndrome and Malassezia Int. Arch. Allergy Immunol. 2002;127(3):161-169. DOI: https://doi.org/10.1159/000053860
Lindborg M., Magnusson C.G.M., Zargari A., et al.: Selective cloning of allergens from the skin colonizing yeast Malassezia furfur by phage surface display technology. J. Invest. Dermatol. 1999;113:156-161. DOI: https://doi.org/10.1046/j.1523-1747.1999.00661.x
Korting H.C., Schaller M.: Neue Entwicklungen in der medizinischen Mykologie. Hautarzt. 2001;52:91-97. DOI: https://doi.org/10.1007/s001050051271
Adamski Z., Deja M.: Nowości i przyszłość w terapii przeciwgrzybiczej. Mikol. Lek. 2005;12(2):115-121.
Aoki Y., Yamamoto M., Hosseini-Mazinani S.M., Koshikawa, N. Sugimoto K., Arisawa M.: Antimicrob. Agents Chemother. 1996;40:127-132. DOI: https://doi.org/10.1128/AAC.40.1.127
Pfaller M.A., et al.: Comparison of visual and spectrophotometric methods for MIC endpoint determinations by using broth microdilution methods to test five antifungal agents including the new triazole DoSyo: Clin. Mikrobiol. 1995;533:1094-1097. DOI: https://doi.org/10.1128/jcm.33.5.1094-1097.1995
Pfaller M.A., et al.: International surveillance of bloodstream infections due to Candida species in the European SENTRY programe: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbol. Infect. Dis. 1999;35:19-25. DOI: https://doi.org/10.1016/S0732-8893(99)00046-2
Marco F., et al.: Activity of Mk-0991 (L-743,872) a new echinocandin compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida sp. Diagn. Microbiol. Infect. Dis. 1998;32:33-37. DOI: https://doi.org/10.1016/S0732-8893(98)00050-9
Didomenico B.: Novel antifungal drugs. Curr. Opin. Microb. 1999;2:509-515. DOI: https://doi.org/10.1016/S1369-5274(99)00009-0
Hryncewicz-Gwóźdź A., Plomer-Niezgoda E., Baran W.: Perspektywy terapii przeciwgrzybiczej. Mikol. Lek. 2003;10:207-211.
DeWet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., Diekmann-Berndt H.: A randomized, double-blind, parallel - group, dose-response study of micafungin compared with fluconazole for treatment of esophagea candidiasis in HIV-positive patients. Clin. Infect. Dis. 2004;15:842-849. DOI: https://doi.org/10.1086/423377
Polak A.: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy. 1978;24(1):2-16. DOI: https://doi.org/10.1159/000237753
Vermes A., et al.: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000;46:171-9. DOI: https://doi.org/10.1093/jac/46.2.171
Zejc A., Gorczyca M.: Chemia leków. Wydawnictwo Lekarskie PZWL, Wydanie II zmienione. 2002;700-703.
Gupta A.K., Skinner A.R.: Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol. 2003;42(1):3-9. DOI: https://doi.org/10.1046/j.1365-4362.42.s1.2.x
Lee J.H., Lee H.S., Eun H.C., et al: Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J. Dermatol. Treat. 2003;14:212-215. DOI: https://doi.org/10.1080/714070652
Sterling T.R., Gasser R.A. Jr , Ziegler A.: Emergence of resistance to amphotericin B during therapy for candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 1996;23:187-188. DOI: https://doi.org/10.1093/clinids/23.1.187
Walsh T.J., Finberg R.W., Arndt C., et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999;340:764-771. DOI: https://doi.org/10.1056/NEJM199903113401004
Prajna N.V., Nirmalan P.K., Mahalakshmi R., Lalitha P., Srinivasan M.: Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis. Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India. Cornea. 2004; 23(8):793-6. DOI: https://doi.org/10.1097/01.ico.0000134193.64357.82
Millns B., Martin M.V.: Nystatin pastilles and suspension in the treatment of oral candidosis. Br. Dent. J. 1996;181:209-11. DOI: https://doi.org/10.1038/sj.bdj.4809214
Gøtzsche P.C., Johansen H.K.: Nystatin prophylaxis and treatment in severely immunodepressed patients. Available in The Cochrane Library; Issue 2. Chichester: Wiley J.: 2004.
Komori T.: Trichomycin B, a polyene macrolide from Streptomyces. Research and Technology Group, Fujisawa Pharmaceutical Co., Ltd., Japan. J. Antibiot. 1990;43(7): 778-82. DOI: https://doi.org/10.7164/antibiotics.43.778
Norgaard O.: Pecilocin allergy. Hautarzt. 1977;28(1):35-6.
O'Sullivan D.P.: Terbinafine: tolerability in general medical practice. Br. J. Dermatol. 1999;141(56):21-5. DOI: https://doi.org/10.1046/j.1365-2133.1999.00010.x
Fuller L.C., et al.: A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br. J. Dermatol. 2001;144:321-7. DOI: https://doi.org/10.1046/j.1365-2133.2001.04022.x
Ablon G., Rosen T., Spedale J.: Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Department of Dermatology, Baylor College of Medicine, USA. Int. J. Dermatol. 1996;35(8):591-3. DOI: https://doi.org/10.1111/j.1365-4362.1996.tb03668.x
Haria M., Bryson H.M.: Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49:103-20. DOI: https://doi.org/10.2165/00003495-199549010-00008
Alchorne M.M., Paschoalick R.C., Forjaz M.H.: Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin. Ther. 1987;9:360-367.
Jones R.N., Bale M.J., Hoban D., et al: In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (Vagistat-1 6.5%) application. Diagn. Microbiol. Infect. Dis. 1993;17:45-51. DOI: https://doi.org/10.1016/0732-8893(93)90069-J
Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190.
Dellenbach P., Thomas J.L., Guerin V., et al: Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int. J. Gynecol. Obstet. 2000;71:47-52. DOI: https://doi.org/10.1016/S0020-7292(00)00348-9
Prajna N.V., John R.K., Nirmalan P.K., et al: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003: 87:1235-1237.
Van Esso D., Fajo G., Losada I., et al: Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin. Ther. 1995;17:264-269. DOI: https://doi.org/10.1016/0149-2918(95)80024-7
Prajna N.V., John R.K., Nirmalan P.K., et al.: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003;87:1235-1237. DOI: https://doi.org/10.1136/bjo.87.10.1235
Fontana C., Cammarata E., Greco M., et al: In vitro activity of fenticonazole on trichomonas vaginalis and gardnerella vaginalis. Curr. Ther. Res. 1990; 48:44-51.
Fioroni A., Terragni L., Vannini P., et al: Fenticonazole plasma levels during treatment with fenticonazole 2% cream and spray in patients with dermatomycoses. Curr. Ther. Res. 1990;47:997-1003.
Gugnani H.C., Akpata L.E., Gugnani M.K., et al: Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses. 1994;37(1-2):39-41. DOI: https://doi.org/10.1111/j.1439-0507.1994.tb00283.x
Lazarov A., Ingber A.: Pustular allergic contact dermatitis to isoconazole nitrate. Am. J. Contact. Derm. 1997;8(4):229-230. DOI: https://doi.org/10.1097/01206501-199712000-00008
Stevens R.E., Konsil J., Verrill S.S., et al: Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J. Clin. Pharmacol. 2002;42:52-60. DOI: https://doi.org/10.1177/0091270002042001006
Fernandez L., Maquiera E., Rodriguez F., et al: Systemic contact dermatitis from miconazole. Contact Dermatitis. 1996;34:217. DOI: https://doi.org/10.1111/j.1600-0536.1996.tb02178.x
Tsunoda S.M., Velez R.L., von Moltke L.L., et al: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 1999;66:461-471. DOI: https://doi.org/10.1016/S0009-9236(99)70009-3
Cuce L.C.: Sulconazole nitrate 1% cream vs clotrimazole 1% cream in the treatment of tinea pedis. Curr. Ther. Res. 1989;45:421-427.
Hajman A.J.: Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. J. Int. Med. Res. 1988;16:367-375. DOI: https://doi.org/10.1177/030006058801600506
Brown D., Henzl M.R., Kaufman R.H. and the Gynazole 1 Study Group.: Butoconazole nitrate 2% for vulvovaginal candidiasis; new, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. J. Reprod. Med. 1999;44:933-938.
Kohl T.D., Martin D.C., Berger M.S.: Comparison of topical and oral treatments for tinea gladiatorum. Clin. J. Sport. Med. 1999; 9(3):161-166. DOI: https://doi.org/10.1097/00042752-199907000-00008
Mselle J.: Use of topical clotrimazole in human keratomycosis. Ophthalmologica. 2001; 215:357-360. DOI: https://doi.org/10.1159/000050885
Woolley P.D., Higgins S.P.: Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. Brit. J. Clin. Pract. 1995;49:65-66.
Plomer-Niezgoda E., Baran E.: Flutrimazol - ocena właściwości farmakologicznych i klinicznych. Mikol. Lek. 2002;9(1):41-44.
Bartroli J., Alquero M., Boncompte E., Forn J.: Synthesis and antifungal activity of series of difluorotritylimizoles. Arzneim.-Forsch./Drug Res. 1992;42:832-855.
Beierdoerffer H: Erfahrungen mit Croconazol in der dermatologischen Praxis. Der Deutsche Dermatologe. 1993;12:1.
Meinicke K., Michel G.: Croconazole: a new broad-spectrum agent in the treatment of fungal skin infections. Int. J. Clin. Pharmacol. Res. 1994;14:139-148.
Amichai B.: Treatment of pityriasis versicolor with a shampoo containing 1% bifonazole (Agispor® shampoo) in children. Clin. Exp. Dermatol. 2000;26:655-660. DOI: https://doi.org/10.1046/j.1365-2230.2000.00730-6.x
Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al.: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190. DOI: https://doi.org/10.1179/joc.1999.11.3.187
Gugnani H.C., Ideyi C., Gugnani M.K.: Oxiconazole in the treatment of tropical dermatomycoses. Curr. Ther. Res. 1993;54:122-125. DOI: https://doi.org/10.1016/S0011-393X(05)80625-3
Pariser D.M., Pariser R.J.: Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis. Cutis. 1994;54:43-44.
Bulkowstein M., Mordish Y., Zimmerman D.R. et al: Ketoconazole-induced neurologic sequelae. Vet. Hum. Toxicol. 2003;45(5):239-240.
Millikan R., Baez L., Banergee T., et al.: Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urologic Oncology. 2001;6:111-115. DOI: https://doi.org/10.1016/S1078-1439(00)00123-X
Moody D.E., Walsh S.L., Rollins D.E., et al: Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin. Pharmacol. Ther. 2004;76(2):154-166. DOI: https://doi.org/10.1016/j.clpt.2004.04.004
Unholzer A., Schinzel S., Nietsch K.H., et al: Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis. A double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin. Drug. Invest. 2002;22(3):167-172. DOI: https://doi.org/10.2165/00044011-200222030-00003
Muijsers R.B.R., et al.: Voriconazole: in the treatment of invasive aspergillosis. Drugs. 2002;62:2655-64. DOI: https://doi.org/10.2165/00003495-200262180-00010
Pearson M.M., et al.: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 2003;37:420-32. DOI: https://doi.org/10.1345/aph.1C261
Pappas P.G., et al.: Alopecia associated with fluconazole therapy. Ann. Intern. Med. 1995; 123:354-7. DOI: https://doi.org/10.7326/0003-4819-123-5-199509010-00006
Bronstein J.A., et al.: Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin. Infect. Dis. 1997;25:1266-7. DOI: https://doi.org/10.1086/516975
Takahashi T., et al.: Desensitization to fluconazole in an AIDS patient. Ann. Pharmacother. 2001;35:642-3. DOI: https://doi.org/10.1345/aph.10285
Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P.: In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 1998;42:313-318. DOI: https://doi.org/10.1128/AAC.42.2.313
Sheehan D.J., Hitchcock C.A., Sibley C.M.: Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999;12:40-79. DOI: https://doi.org/10.1128/CMR.12.1.40
Meletiadis J., et al.: In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 2000;44:470-2. DOI: https://doi.org/10.1128/AAC.44.2.470-472.2000
Goldman M., et al.: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob. Agents Chemother. 2000;44:1585-7. DOI: https://doi.org/10.1128/AAC.44.6.1585-1587.2000
Dannaoui E., et al.: Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 2001;47:333-340. DOI: https://doi.org/10.1093/jac/47.3.333
Garcia F.R.G., Sauceda L., Ramirez P.D., Cruz T.F., Romero C.R.: Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis. Ginecol. Obstet. Mex. 2000;68:154-9.
Courtney R., Pai S., Laughlin M., et al.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003;47:2788-2795. DOI: https://doi.org/10.1128/AAC.47.9.2788-2795.2003
Courtney R., Radwanski E., Lim J., et al: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 2004;48:804-808. DOI: https://doi.org/10.1128/AAC.48.3.804-808.2004
Herbrecht R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 2004;58(6):612-624. DOI: https://doi.org/10.1111/j.1368-5031.2004.00167.x
Segal B.H. et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 2005;40:1684-8. DOI: https://doi.org/10.1086/430068
Carrillo-Munoz A.J., Quindos G., Lopez-Ribot J.L.: Current Developments in Anti-Fungal Agents. Current Medicinal Chemistry - Anti-Infective Agents. 2004;3(27):297-323. DOI: https://doi.org/10.2174/1568012043353766
Sorbera, L.A., Bartroli, J., Castaner, J.: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 2004;48(2):384-7. DOI: https://doi.org/10.1128/AAC.48.2.384-387.2004
Benfield P. Clissold S.P.: Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1988;35:143-153. DOI: https://doi.org/10.2165/00003495-198835020-00004
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.